The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 24, 2015

Filed:

Mar. 07, 2013
Applicant:

Institute of Cancer Research: Royal Cancer Hospital (The), London, GB;

Inventors:

Alan Ashworth, London, GB;

Christopher James Lord, London, GB;

Richard James Rowland Elliot, London, GB;

Dan Niculescu-Duvaz, Sutton, GB;

Roderick Porter, London, GB;

Raymond John Boffey, Cambridge, GB;

Melanie Jayne Bayford, Cambridge, GB;

Stuart Firth-Clark, Cambridge, GB;

Ashley Nicholas Jarvis, Cambridge, GB;

Trevor Robert Perrior, Cambridge, GB;

Rebekah Elisabeth Key, Cambridge, GB;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 401/04 (2006.01); A61K 31/4725 (2006.01); C07D 217/24 (2006.01); C07D 401/14 (2006.01); C07D 217/14 (2006.01); C07D 217/16 (2006.01); C07D 401/10 (2006.01); C07D 401/12 (2006.01); C07D 405/12 (2006.01); C07D 487/04 (2006.01); C07D 487/08 (2006.01); C07D 487/10 (2006.01);
U.S. Cl.
CPC ...
C07D 217/24 (2013.01); C07D 217/14 (2013.01); C07D 217/16 (2013.01); C07D 401/04 (2013.01); C07D 401/10 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 405/12 (2013.01); C07D 487/04 (2013.01); C07D 487/08 (2013.01); C07D 487/10 (2013.01);
Abstract

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted-2H-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.) and/or Wnt signalling. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to inhibit Wnt signalling; to treat disorders that are ameliorated by the inhibition of PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to treat disorders that are ameliorated by the inhibition of Wnt signalling; to treat proliferative conditions such as cancer, etc.


Find Patent Forward Citations

Loading…